Skip to main content
[Preprint]. 2023 Jan 2:2023.01.01.522436. [Version 1] doi: 10.1101/2023.01.01.522436

Fig. 2. RIPTAC differential biology in 293_HFL model system.

Fig. 2

a) Structures of HaloTag-FKBP fusion protein targeting RIPTACs with JQ1, TMX3013, BI-2536, or dinaciclib as effector ligands b) Differential anti-proliferative activity of select covalent RIPTACs in target protein expressing 293_HFL cells in a 7-day Cell TiterGlo assay c) Differential anti-proliferative activity of select non-covalent RIPTACs in a 7-day Cell TiterGlo assay. d) GI50 values and fold-shift over 293_GFPL cells, obtained under continuous 7-day treatment with the optimal linker length from each RIPTAC series. All data representative of 3 independent experiments (N=3)